Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:AVAI)

0.1153 +0.0141 (+13.93%)
Streaming Delayed Price Updated: 3:45 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AVAI

< Previous 1 2 3 4 5 Next >
News headline image
Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick
A look at the three approaches competing to help beta cell replacement survive the immune system 
From Biotech Insider
Via GlobeNewswire
News headline image
Avaí Bio and Austrianova Announce Research Collaboration with San Raffaele Hospital to Advance Encapsulated Cell Therapy for Diabetes
Agreement combines Austrianova’s Cell-in-a-Box® technology with San Raffaele Hospital’s stem cell-derived beta cell expertise through a research collaboration with Avaí Bio and Austrianova’s JV... 
From Avaí Bio, Inc.
Via GlobeNewswire
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:BIOA),(NYSE:LCTX),(NASDAQ:FATE) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Five Under-the-Radar Stocks With Catalysts Already in Motion — Across AI Defense, Space, Longevity, Gold, and Post-Quantum Security
From World Street Intelligence
Via GlobeNewswire
News headline image
The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met 
From Equity Insider
Via GlobeNewswire
News headline image
Biotech Brief: Avaí Bio and Austrianova to Present Latest Data on Klotho Anti-Aging Therapy at Annual Klotho Conference
Las Vegas, NV – April 7, 2026 – Avaí Bio, Inc. (OTCQB: AVAI) (“Avaí” or the “Company”), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related... 
Via FinancialNewsMedia
News headline image
The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t Noticed
AVAI, FBLG, FATE, MESO, and LGVN as Regenerative Medicine Moves From Lab to GMP Manufacturing Facilities 
From USA News Group
Via GlobeNewswire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
5 Stocks Sitting on the Right Side of the Biggest Repricing in a Generation
Issued on behalf of GoldHaven Resources Corp. 
From USA News Group
Via GlobeNewswire
News headline image
THE RESILIENCE DOCTRINE: 5 Assets Securing the 2026 Sovereign Stack
Issued on behalf of Ventripoint Diagnostics Ltd. 
From Equity Insider
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
THE SOVEREIGN MANDATE: 5 Stocks Securing the 2026 Choke Points
Issued on behalf of QSE - Quantum Secure Encryption Corp. 
From USA News Group
Via GlobeNewswire
News headline image
THE FOUNDATION TRADE: 5 Assets Anchoring the Next Industrial Cycle
Issued on behalf of GoldHaven Resources Corp. 
From USA News Group
Via GlobeNewswire
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
Issued on behalf of Ventripoint Diagnostics Ltd. 
From USA News Group
Via GlobeNewswire
News headline image
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
From Avant Technologies Inc.
Via Business Wire
News headline image
THE CRITICAL LIST: 5 Stocks Anchoring the New Economy
From USA News Group
Via GlobeNewswire
News headline image
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
Issued on behalf of Oncolytics Biotech Inc. 
From USA News Group
Via GlobeNewswire
News headline image
The Biotech Sector is Seeing a Major Boost From Programmable Cell Therapies in Chronic Disease Care
From USA News Group
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Avant Technologies and Austrianova Secure Exclusive License for Klotho Producing Cell Line to Advance Anti-Aging Therapies
From Avant Technologies, Inc.
Via Business Wire
News headline image
Avant Technologies Signs Joint Venture to Advance Cell-Based Diabetes Treatment
From Avant Technologies Inc.
Via Business Wire
News headline image
Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies
Las Vegas, NV – September 18, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), a Nevada-based corporation, and Austrianova (SGAustria Pte. Ltd.), a Singapore-based... 
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Avant Technologies’ Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
Las Vegas, NV – July 22, 2025 – Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging technology company developing healthcare solutions using both artificial intelligence (AI)... 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Ainnova Tech Reaches Major FDA Milestone in AI-Powered Diabetic Retinopathy Detection
Via AB Newswire
Topics Artificial Intelligence
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.